Embodied AI Xingdong Jiyuan raises 10B yuan at 100B+ val

Post LinkedIn

🔥Read original on 36氪

#embodied-ai#robotics-funding#strategic-roundxingdong-jiyuanxingdong-jiyuansamsungsingtel

💡China embodied AI unicorn at $14B val—key for robotics builders

⚡ 30-Second TL;DR

What Changed

10 billion yuan strategic round completed recently

Why It Matters

Highlights surging VC interest in China's embodied AI sector, accelerating robotics hardware and software advances.

What To Do Next

Benchmark Xingdong Jiyuan's humanoid robot demos against Unitree for your embodied AI projects.

Who should care:Founders & Product Leaders

Key Points

•10 billion yuan strategic round completed recently
•Valuation surpasses 100 billion yuan
•New investors: Samsung, Singtel, Youli Capital (Korea), Zhongjin Porsche
•Oversubscribed; 2 months after last round

🧠 Deep Insight

Background and context from public sources — not the original article. 5 sources cited.

🔑 Enhanced Key Takeaways

•Xingdong Jiyuan, also known as AgiBot Robotics, was founded in February 2023 as a Tsinghua University spin-off by former Huawei executives Deng Taihua (CEO) and Peng Zhihui (Zhi Hui Jun).[4]
•The company develops full-stack robotics systems including Yuan Zheng, Jing Ling, and Ling Xi robots for services, industrial automation, logistics, and education, and launched the Qiyuan embodied foundation model in March 2025 enabling learning from human videos.[4]
•Prior to the 10B yuan round, Xingdong Jiyuan completed a Series A of 500 million yuan in July 2024 and Series A+ of 1 billion yuan in June 2025, with investors including Tencent, JD.com, Sequoia China, and Hillhouse.[2][4]

🔮 Future ImplicationsAI analysis grounded in cited sources

AgiBot could become the first embodied intelligence firm listed on STAR Market

Through its $290M acquisition of Swancor, AgiBot positions itself to list via backdoor listing ahead of rivals like Unitree, leveraging existing public infrastructure for rapid scaling.[4]

Pharmacy scenarios enable early data accumulation for Xingdong Jiyuan

Investors selected Meituan Pharmacy for pilots due to customer willingness to pay premiums, tolerance for efficiency trade-offs, and high error forgiveness, facilitating real-world data collection unlike rigid factory settings.[1]